Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 2, 2020 (6 years ago)

Finasteride Plus 1.25mg Capsule

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Processing Controls (lack of assurance of conformity to specifications).

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Finasteride Plus 1.25mg Capsule, 90 capsules per bottle, MasterPharm, 115-02 Liberty Ave, Richmond Hill, NY 11419, (866) 630-5600

Drug: Finasteride

Recalling firm
MasterPharm LLC
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1422-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Finasteride recalls

See all
Class II · Moderate risk

Finasteride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-6976-3 D-0516-2023
Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk

Finasteride Tablets USP 1 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 71713-096-90 D-0391-2023

Other recalls by MasterPharm LLC

All 2020 recalls
Class II · Moderate risk

Vardenafil 20 mg Troche

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1442-2020
Class II · Moderate risk

Tadalafil 7 mg Capsule

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1440-2020